Cellipont Bioservices News and Resources

Cellipont Bioservices has entered into an agreement with biopharmaceutical company Mongoose Bio to support the technology transfer, process development, and clinical-grade manufacturing of Mongoose’s autologous TCR-T cell therapy, MGB-001. The partnership will focus on delivering this advanced therapy, designed to

Cellipont Bioservices, a cell therapy Contract Development and Manufacturing Organization (CDMO), has named Darren Head as its new Chief Executive Officer. Head, who also serves as Chairman of the Board, brings over 26 years of experience in biopharmaceutical leadership and

Cellipont Bioservices, a cell therapy Contract Development and Manufacturing Organisation (CDMO), has announced a strategic partnership with Adva Biotechnology, an Israel-based private biotech company. The collaboration will see Cellipont leverage Adva Biotechnology’s ADVA X3 platform in North America, a move